Chemistry: analytical and immunological testing – Biospecific ligand binding assay
Reexamination Certificate
2006-07-13
2010-12-28
Yu, Misook (Department: 1642)
Chemistry: analytical and immunological testing
Biospecific ligand binding assay
C436S518000, C435S007230
Reexamination Certificate
active
07858395
ABSTRACT:
The invention relates to antibodies for use for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical and diagnostical compositions comprising such antibodies. The invention also relates to a method for identifying and/or scoring prostate carcinomas. Furthermore, the invention relates to the use of at least one siRNA (“short interfering RNA”) and/or at least one anti-LSD1 antibody for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal or for the manufacture of a medicament for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to a pharmaceutical composition for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one siRNA and/or at least one anti-LSD1 antibody suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to a method for controlling the androgen receptor-dependent gene expression in a mammal, said process comprising the step of administering to said mammal, on a suitable route, an effective dose of a pharmaceutical composition modulating an activity of the lysine-specific demethylase (LSD1) in a mammal.
REFERENCES:
patent: 2004/0121413 (2004-06-01), Aebersold et al.
patent: 1693062 (2006-08-01), None
patent: 1693383 (2006-08-01), None
patent: 2006/071608 (2006-07-01), None
Y. Shi et al., “Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1”Cellvol. 119, pp. 941-953 (2004).
E. Metzger et al., “LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription”Naturevol. 437, pp. 436-439 (2005).
D.B. Seligson et al., “Global histone modification patterns predict risk of prostate cancer recurrence”, Nature, vol. 435, pp. 1262-1266 (2005).
M. Breslow et al. “Latent carcinoma of prostate at autopsy in seven areas”Int. J. Cancervol. 20, pp. 680-688 (1977).
A.C.B. Cato et al., “The androgen receptor as a mediator of gene expression and signal transduction pathways”Trends Endocrinol. Metab. vol. 9, pp. 150-154 (1998).
S.R. Denmeade et al., “A history of prostate cancer treatment”Nat. Rev. Cancervol. 2, pp. 389-396 (2002).
J.W. Waterbor et al., “Prostate Cancer Screening (United States)”Cancer Causes and Controlvol. 6, pp. 267-274 (1995).
C.K. Glass et al., “The coregulator exchange in transcriptional functions of nuclear receptors”Genes Dev. vol. 14, pp. 121-141 (2000).
B.D. Strahl et al., “The language of covalent histone modifications”Naturevol. 403, pp. 41-45 (2000).
Y. Shi et al., “Coordinated histone modifications mediated by a CtBP co- repressor complex”Naturevol. 422, pp. 735-738 (2003).
M.A. Hakimi et al. “A candidate X-linked mental retardation gene is a component of a, new family of histone deacetylase-containing complexes”J. Biol. Chem. vol. 278, pp. 7234-7239 (2003).
M.A. Hakimi et al. “A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes”Proc. Natl. Acad. Sci. USAvol. 99, pp. 7420-7425 (2002).
S. Eimer et al., “Loss ofspr-5 bypasses the requirement for theC. eleganspresenilinsel-12 by derepressinghop-1”EMBO J.vol. 21, pp. 5787-5796 (2002).
J. M. Müller et al., “FHL2, a novel tissue-specific coactivator of the androgen receptor”EMBO J.vol. 19, pp. 359-369 (2000).
J. M. Müller et al., “The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus”EMBO J.vol. 21, pp. 736-748 (2002).
Y. Shang et al., “Formation of the androgen receptor transcription complex”Molecular Cellvol. 9, pp. 601-610 (2002).
L. Shatkina et al., “The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor”Mol. Cell. Biol. vol. 23, pp. 7189-7197 (2003).
Z. Kang et al., “Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex”J. Biol. Chem. vol. 277, pp. 48366-48371 (2002).
E. Metzger et al., “A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer”EMBO J. vol. 22, pp. 270-280 (2003).
M. Wiznerowicz et al., “Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference”J. Virol. vol. 77, pp. 8957-8961 (2003).
M.W. Pfaffl et al. “Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR”Nucleic Acids Res. vol. 30, e36 (2002).
T.E. O'Neill et al., “Nucleosome arrays inhibit both initiation and elongation of transcripts by bacteriophage T7 RNA polymerase”J. Mol. Biol. vol. 223, pp. 67-78 (1992).
R. Schüle et al., “Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor”Cellvol. 62, pp. 1217-1226 (1990).
G. Verrijdt et al., “Functional interplay between two response elements with distinct binding characteristics dictates androgen specificity of the mouse sex-limited protein enhancer”J. Biol. Chem. vol. 277, pp. 35191-35201 (2002).
Z. Sun et al., “Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes”Nucleic Acids Res. vol. 25, pp. 3318-3325 (1997).
T.R. Brummelkamp et al., “A system for stable expression of short interfering RNAs in mammalian cells”Sciencevol. 296, pp. 550-553 (2002).
E.F. Greiner et al., “Differential ligand-dependent protein-protein interactions between nuclear receptors and a neuronal-specific cofactor”Proc. Natl. Acad. Sci. USAvol. 97, pp. 7160-7165 (2000).
R. Schüle et al., “Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene”Cellvol. 61, pp. 497-504 (1990).
R. Schneider et al., “Direct binding of INHAT to H3 tails disrupted by modifications”J. Biol. Chem. vol. 279, pp. 23859-23862 (2004).
G. Rigaut et al., “A generic protein purification method for protein complex characterization and proteome exploration”Nat. Biotechnol. vol. 17, pp. 1030-1032 (1999).
Abstract of T. Bocker et al., “In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate”J. Modern Pathologyvol. 8, No. 3, pp. 226-231 (1995).
Buettner Reinhard
Metzger Erich
Schuele Roland
Greenblum and Bernstein P.L.C.
Rheinische Friedrich-Wilhelms-Universitaet Bonn
Universitaetsklinikum Freiburg
Yu Misook
LandOfFree
Antibodies for use in identifying and/or scoring prostate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies for use in identifying and/or scoring prostate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies for use in identifying and/or scoring prostate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4214894